CELLULAR immunity to encephalitogenic factor (EF)inpatients with malignant neoplasia has been demonstrated on a number of occasions, using both the macrophage electrophoretic mobility (MEM) test (Field and Caspary, 1970; Goldstone et al., 1973; Pritchard et al., 1972) and the macrophage migration inhibition (MMI) test (Shelton et al., 1975; Light et al., 1975; . The demonstration by Caspary and Field (1971) that lymphocytes from cancer patients also respond to an acid extract of tumour tissues in the MEM test led to the proposal that the lymphocyte response to EF in malignant disease represented a response to neoantigens on the tumour cell surface immunologically cross-reactive with EF. This acid-extractable protein from malignant tissues has been called cancer basic protein (CaBP) . In support of this hypothesis, McDermott et al. (1974) and Coates and Carnegie (1975) have presented evidence for the sharing of antigenic determinants between EF and CaBP. Moreover, Dickinson et al. (1972) have demonstrated that the antigenic activity of CaBP in tumour cells grown in vitro is associated exclusively with the plasma membrane.
Studies in hamsters bearing transplanted SV40-induced tumours have shown that a spleen-cell response to EF develops in these animals 10-21 days after tumour implantation (Shelton et al., 1975; 4/8 4/8 6/10 8/10 9/10 9/10 9/10 2/10 4/10 8/10 10/10 0/10 0/10 6/9 9/9 7/9 7/9 2/8 9/9 7/9 0/10 0/10 0/10 0/10 2/10 3/10 6/9 6/8 7/8 0/10 0/10 3/8 3/8 6/8 7/8 9/9 9/9 9/9 5/9 5/9 9/9 9/9 8/8 0/9 2/9 5/10 6/10 7/7 In a second set of experiments, the Winn adoptive-transfer assay (Winn, 1961) Groups of 10 hamsters were inoculated s.c. with 0.1 ml of a given cell mixture into the left flank, and the incidence of tumours in these animals over a 16-day period is shown in Table II . Spleen cells from tumour-bearing animals, when mixed with tumour cells at a ratio of 100:1, significantly reduced the growth rate of tumours when compared with control animals. Thus, this assay system was capable of detecting transplantation-type immunity to the SV40 tumour. In contrast, cells from animals immunized with EF or CaBP gave no protection against SV40-tumour growth, at spleen cell: tumour cell ratios of 10:1 or 100:1. These results are interpreted as showing that EF or CaBP sensitization does not give protection against SV40-tumour growth, and is evidence against the hypothesis that the delayed hypersensitivity response to EF seen in malignant neoplasia is an inmmunological reaction directed against a neoantigen(s) on the tumour-cell surface. However, it has been demonstrated that embryonic antigens expressed on the surface of certain experimental animal tumour cells are not always capable of inducing transplantation-type immunity (Chism et al., 1976; Basombrio and Prehn, 1972) . Both these effects may be related to the density of antigenic determinants on the tumour-cell surface, to a rapid turnover of antigen or to sequestration of antigen, which might allow the tumour to escape from immunological cytotoxic reactions directed against the antigen. Whilst immunization with EF or CaBP does not appear to induce transplantation-type immunity to the SV40 tumour in the assay systems employed in the present study, this should not be taken as conclusive evidence that the delayed hypersensitivity response to EF seen in animals bearing SV40 tumours is not due to an immunological reaction directed against neoantigen(s) on the tumour-cell surface.
